- This event has passed.
March 17 - March 19
The transformative era of kidney drug development is here, with 2024 bringing landmark advancements, including Novartis’ Borealis Biosciences and approvals in IgAN, Travere Therapeutics, and industry-defining acquisitions by Biogen and Vertex. Breakthrough therapies like SGLT2 inhibitors, GLP-1s, and MRAs continue to reshape the CKD treatment paradigm, while the FDA’s accelerated pathways fuel unprecedented innovation. We are witnessing a renaissance in chronic kidney disease research and development and treatment.
